Gracevit received approval for manufacture and marketing from the Japanese Ministry of Health, Labour and Welfare on January 25 and attained the National Health Insurance drug price listing on April 18, 2008.
Daiichi Sankyo currently markets Cravit, which is said to be highly acclaimed for its clinical efficacy and safety in tablet form and as a fine granular preparation. However, Gracevit exhibits potent antibacterial activity with a broad spectrum and is expected to be the new quinolone oral antibacterial agent, clinically effective in severe cases of bacterial infection, relapse/recrudescence of infection and infections where resistant bacteria are the suspected cause.
In addition to Cravit, Daiichi Sankyo is confident Gracevit can further contribute to the treatment of infectious diseases.